Human Studies / PROGRESS
Pharmacogenetics
PhaRmacogenetics Of the Glycemic RESponse to SGLT2 Inhibitors
PROGRESS is studying dapagliflozin (Farxiga) to understand the role of a patient’s genetic makeup in choosing what diabetes drug to prescribe. It’s one of the first pharmacogenetic investigations of SGLT2 inhibitors involving the acute response.
Study Design
Aims & What Study Visits Involve
Aims
- Use genetics, metabolomics, and proteomics to understand how SGLT2 inhibitors work.
- Assess whether genetic risk or SLC5A2 variation influences response to SGLT2 inhibitors.
What Study Visits Involve
- A screening visit, followed by two five-hour visits a week apart.
- Blood draws, glucose checks, and urine collection at each visit.
- Taking the study drug daily for 5 days at home.